Výsledky vyhledávání

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Platelet function defects in patients with Gaucher disease on long term ERT- implications for evaluation at bleeding challenges

Autor: Komninaka, V. Repa, K. Marinakis, T. Pouliakis, A. Koutsouri, T. Tsokanas, D. Flevary, P. Voskaridou, E. Politou, M.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::b8f94e4789ec48565b75abd2d83f2be9
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078532

Zobrazit plný text záznamu

Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry

Autor: Diamantopoulos, P.T. Pappa, V. Symeonidis, A. Kotsianidis, I. Galanopoulos, A. Papadaki, H. Anagnostopoulos, A. Vassilopoulos, G. Zikos, P. Hatzimichael, E. Papaioannou, M. Megalakaki, A. Kotsopoulou, M. Repousis, P. Dimou, M. Solomou, E. Pontikoglou, C. Kyriakakis, G. Tsokanas, D. Papoutselis, M.-K. Papageorgiou, S. Kourakli, A. Panayiotidis, P. Viniou, N.-A.

Background: Hypomethylating agents have altered the prognosis of myelodysplastic syndrome (MDS) so that long-term survival is now a feasible treatment goal. Patients and Methods: We analyzed data from patients with MDS treated with 5-azacytidine reco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::9769b866e314facc62de343ca9b5b9f0
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078653

Zobrazit plný text záznamu

Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes

Autor: Papadopoulos, V. Diamantopoulos, P.T. Papageorgiou, S.G. Papoutselis, M. Vrachiolias, G. Pappa, V. Galanopoulos, A.G. Vassilakopoulos, T.P. Hatzimichael, E. Zikos, P. Papadaki, H.A. Bouchla, A. Panayiotidis, P. Megalakaki, A. Papaioannou, M. Liapis, K. Dryllis, G. Tsokanas, D. Kourakli, A. Symeonidis, A. Viniou, N.-A. Kotsianidis, I.

Higher-risk Myelodysplastic syndromes (MDS) patients undergoing treatment with 5-azacytidine (AZA) are typically elderly with several comorbidities. However, the effect of comorbidities on the effectiveness and safety of AZA in real-world settings re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::ca0c7e0bcadf9cf7dcd2d4a67fd80dee
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078476

Zobrazit plný text záznamu

Azacytidine failure revisited: An appraisal based on real-life data from the MDS registry of the hellenic myelodysplastic syndrome study group (HMDS)

Autor: Kotsianidis, I. Papageorgiou, S.G. Pappa, V. Galanopoulos, A.G. Viniou, N.-A. Vassilakopoulos, T.P. Papoutselis, M. Vrachiolias, G. Papadopoulos, V. Diamantopoulos, P.T. Tsokanas, D. Kourakli, A. Symeonidis, A.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::73a99807d9112e5a3e8c743722f90ce4
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3106516

Zobrazit plný text záznamu

Chronic myelomonocytic leukemia treated with 5-azacytidine–results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system

Autor: Diamantopoulos, P.T. Kotsianidis, I. Symeonidis, A. Pappa, V. Galanopoulos, A. Gogos, D. Karakatsanis, S. Papadaki, H. Palla, A. Hatzimichael, E. Dimou, M. Papageorgiou, S. Delimpasis, S. Papaioannou, M. Papoutselis, M. Kourakli, A. Tsokanas, D. Anagnostopoulos, A. Kontos, C.K. Panayiotidis, P. Viniou, N.-A. On behalf of the Hellenic MDS study group

Hypomethylating agents are widely used in chronic myelomonocytic leukemia (CMML). We analyzed the characteristics of 88 patients with CMML homogeneously treated with 5-azacytidine (Hellenic 5-Azacytidine Registry). The overall response rate was 48.9%

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::accdb140d9f39aae2b435439abe8e612
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078097

Zobrazit plný text záznamu

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry

Autor: Diamantopoulos, P. Koumbi, D. Kotsianidis, I. Pappa, V. Symeonidis, A. Galanopoulos, A. Zikos, P. Papadaki, H.A. Panayiotidis, P. Dimou, M. Hatzimichael, E. Vassilopoulos, G. Delimpasis, S. Mparmparousi, D. Papageorgiou, S. Variami, E. Kyrtsonis, M.-C. Megalakaki, A. Kotsopoulou, M. Repousis, P. Adamopoulos, I. Kontopidou, F. Christoulas, D. Kourakli, A. Tsokanas, D. Konstantinos Papoutselis, M. Kyriakakis, G. Viniou, N.-A. the Hellenic MDS study group

In patients with myelodysplastic syndrome (MDS), the prognostic significance of chromosome 17 abnormalities has not yet been fully elucidated, except for isochromosome 17q that has been characterized as an intermediate risk abnormality in the Revised

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::ce5198a9deb75623d6bd5a5afc708c09
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078566

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání